2 days ago
Patterson-UTI Energy, Inc. (NASDAQ:PTEN) reported on September 7 that it averaged 101 revenue-earning drilling rigs in the United States during August and 100 over the two months ended August 31.
The count measures rigs earning revenue under drilling contracts. The announcement provided no day rates, contract duration, utilization by rig class, or margins. Management explicitly cautioned that rig-count trends alone may not indicate financial performance.
For investors, the update supplies evidence that customers are putting equipment to work. Whether that activity produces better returns depends on the revenue earned and costs incurred for each contracted rig.
The two-month average is consistent with management's earlier outlook for approximately 100 U.S. rigs in the third quarter, compared with 92 in the second quarter. That supports an activity recovery from the prior quarter, although September will determine the final quarterly average.
There is also pricing evidence outside the monthly release. In its July 29 results, Patterson-UTI Energy, Inc. (NASDAQ:PTEN) said recently awarded term contracts carried approximately 10% to 15% higher pricing than levels at the start of the year. Management attributed that improvement to higher demand and customer interest in structural rig upgrades. Those increases applied to recently awarded contracts, rather than the entire fleet.
#rigs #energy #pten
The count measures rigs earning revenue under drilling contracts. The announcement provided no day rates, contract duration, utilization by rig class, or margins. Management explicitly cautioned that rig-count trends alone may not indicate financial performance.
For investors, the update supplies evidence that customers are putting equipment to work. Whether that activity produces better returns depends on the revenue earned and costs incurred for each contracted rig.
The two-month average is consistent with management's earlier outlook for approximately 100 U.S. rigs in the third quarter, compared with 92 in the second quarter. That supports an activity recovery from the prior quarter, although September will determine the final quarterly average.
There is also pricing evidence outside the monthly release. In its July 29 results, Patterson-UTI Energy, Inc. (NASDAQ:PTEN) said recently awarded term contracts carried approximately 10% to 15% higher pricing than levels at the start of the year. Management attributed that improvement to higher demand and customer interest in structural rig upgrades. Those increases applied to recently awarded contracts, rather than the entire fleet.
#rigs #energy #pten
3 months ago
We recently compiled a list of the 10 Best Weight Loss Drug Stocks to Buy in 2026. AstraZeneca PLC (NYSE:AZN) is one of the best weight loss drugs on this list.
TheFly reported on June 15 that AZN announced that its supplemental Biologics License Application (sBLA) for Ultomiris (ravulizumab) was accepted and granted Priority Review by the U.S. Food and Drug Administration (FDA). The application seeks approval for the treatment of adults with immunoglobulin A nephropathy (IgAN), a rare kidney disorder. The FDA's Priority Review designation is given to therapies that have the potential to provide meaningful improvements in treatment options through benefits such as improved safety, effectiveness, or patient care. The FDA's final decision on the application is expected in the fourth quarter of 2026.
15 States with the Best Healthcare in the US
This regulatory milestone closely follows another major commercial victory for the company's oncology franchise. On June 12, AstraZeneca PLC (NYSE:AZN) announced that the U.S. Food and Drug Administration approved Truqap (capivasertib) in combination with abiraterone and prednisone for the treatment of adults with PTEN-deficient metastatic prostate cancer. The approval applies to patients with metastatic androgen pathway modulation-naive or sensitive disease, identified through an FDA-authorized diagnostic test. The decision positions Truqap as a targeted treatment option for this specific patient population and expands AstraZeneca's oncology portfolio with a new approach for managing advanced prostate cancer.
AstraZeneca PLC (NYSE:AZN) is a global biopharma company and is expanding into the obesity market with next-generation weight-loss therapies, including oral GLP-1 drugs and monthly injectables. The company aims to compete with market leaders while combining obesity treatments with its strong cardiovascular and metabolic disease portfolio.
TheFly reported on June 15 that AZN announced that its supplemental Biologics License Application (sBLA) for Ultomiris (ravulizumab) was accepted and granted Priority Review by the U.S. Food and Drug Administration (FDA). The application seeks approval for the treatment of adults with immunoglobulin A nephropathy (IgAN), a rare kidney disorder. The FDA's Priority Review designation is given to therapies that have the potential to provide meaningful improvements in treatment options through benefits such as improved safety, effectiveness, or patient care. The FDA's final decision on the application is expected in the fourth quarter of 2026.
15 States with the Best Healthcare in the US
This regulatory milestone closely follows another major commercial victory for the company's oncology franchise. On June 12, AstraZeneca PLC (NYSE:AZN) announced that the U.S. Food and Drug Administration approved Truqap (capivasertib) in combination with abiraterone and prednisone for the treatment of adults with PTEN-deficient metastatic prostate cancer. The approval applies to patients with metastatic androgen pathway modulation-naive or sensitive disease, identified through an FDA-authorized diagnostic test. The decision positions Truqap as a targeted treatment option for this specific patient population and expands AstraZeneca's oncology portfolio with a new approach for managing advanced prostate cancer.
AstraZeneca PLC (NYSE:AZN) is a global biopharma company and is expanding into the obesity market with next-generation weight-loss therapies, including oral GLP-1 drugs and monthly injectables. The company aims to compete with market leaders while combining obesity treatments with its strong cardiovascular and metabolic disease portfolio.
